- Tumors1000+
- Cancer1000+
- Pathology1000+
- Pathologic Processes1000+
- Nervous System Diseases1000+
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer1000+
- Pathology1000+
- Pathologic Processes1000+
- Nervous System Diseases1000+
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- HER2 positive
- PD-L1 positive
- EGFR positive
- PR positive
- KRAS positive
- PR negative
- ER negative
- BRAF positive
- EGFR negative
- PD-L1 negative
- IDH positive
- p16 positive
- CD19 positive
- HLA-A positive
- ALK negative
- BRCA1 positive
- BRCA2 positive
- ALK positive
- CD20 positive
- HLA positive
- IDH negative
- MET positive
- TP53 positive
- ROS1 positive
- MYC positive
- HR positive
- HLA negative
- MSI-H positive
- FLT3 positive
- PALB2 positive
- ROS1 negative
- p16 negative
- BRAF negative
- RB1 negative
- RB1 positive
- HLA-A negative
- NRAS positive
- dMMR positive
- HPV positive
- NF1 positive
- PIK3CA positive
- RET positive
- BRCA positive
- MET negative
- CD22 positive
- RAS positive
- ATM positive
- BCL2 positive
- NTRK positive
- HPV negative
- MGMT negative
- BCL6 positive
- CFTR positive
- MLH1 positive
- MSH6 positive
- CD30 positive
- MMR positive
- MSH2 positive
- PMS2 positive
- ARID1A positive
- KRAS negative
- anti-dsDNA positive
- BCR-ABL1 positive
- BRIP1 positive
- CCND1 positive
- KIT positive
- PTEN positive
- Philadelphia chromosome positive
- ANA positive
- CHEK2 positive
- HRAS positive
- HbSS positive
- MGMT positive
- NPM1 positive
- CD123 positive
- PD-1 positive
- RAS negative
- ctDNA positive
- CD33 positive
- FGFR2 positive
- KMT2A positive
- RAD51 positive
- RAD51C positive
- HBV DNA negative
- MSI positive
- MSS positive
- MTAP positive
- NTRK1 positive
- RAD51D positive
- RET negative
- EPCAM positive
- FGFR3 positive
- HBsAg positive
- MMR negative
- MSI negative
- PD-1 negative
- STK11 positive
- anti-Sm positive
- p53 positive
- t(11;14) positive
- AR positive
- ASXL1 positive
- BRCA negative
- CDK4 positive
- CLDN18.2 positive
- FGFR positive
- GPC3 positive
- HBV DNA positive
- HBsAg negative
- MSI-H negative
- NF2 positive
- NRAS negative
- RUNX1 positive
- TP53 negative
- ZnT8 positive
- BARD1 positive
- CD19 negative
- CD3 positive
- FANCA positive
- HPV16 positive
- MSS negative
- NTRK negative
- APC positive
- APOE ε4 positive
- BCR-ABL positive
- CD4 positive
- DMD positive
- EZH2 positive
- FLT3 negative
- FMR1 positive
- HR negative
- HbSC positive
- IA-2 positive
- JAK2 positive
- PDGFRA positive
- RAF positive
- RF positive
- SMARCA4 positive
- SMN1 positive
- T790M positive
- dMMR negative
- ABCA4 positive
- BAP1 positive
- BRCA1 negative
- BRCA2 negative
- CCNE1 positive
- CD4 count positive
- CD5 positive
- CD70 positive
- CDK12 positive
- CEA positive
- DLL3 positive
- EBV positive
- GATA2 positive
- GRN positive
- HBcAb negative
- Ki-67 positive
- MECP2 positive
- NF1 negative
- PTEN negative
- PTPN11 positive
- Ph positive
- RAD54L positive
- TERT positive
- TROP2 positive
- del(17p) positive
- pMMR positive
- t(14;16) positive
- t(4;14) positive
- t(9;22) positive
- \-7 positive
- AKT1 positive
- APOL1 positive
- B7-H3 positive
- CD38 positive
- CDK6 positive
- CHEK1 positive
- CLDN6 positive
- COL7A1 positive
- Complex karyotype positive
- DMPK positive
- DNMT3A positive
- ER or PR positive
- FANCL positive
- FRα positive
- H3K27M positive
- HBB positive
- HBcAb positive
- HRD positive
- HbSβ0-thalassemia positive
- ICA positive
- L858R positive
- MDM2 positive
- MLH1 negative
- MLL rearrangement positive
- MSH2 negative
- MSH6 negative
- NBN positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Grade 5
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 or more Spontaneous Breathing Trials (SBTs)
- 1927nm Fractional Thulium Laser Treatment
- 30-day washout period after Erythropoietin-Stimulating Agent or IV Iron
- Activity Modification
- Adalimumab
- Adjuvant Chemotherapy without Concurrent Biologic/Targeted Therapy
- Adjuvant Radiation Therapy
- Adjuvant Therapy (except reconstruction)
- Adverse Event from Previous Treatment (Excluding Alopecia, Cutaneous Toxicity, Peripheral Neuropathy, Fatigue Grade ≤ 2)
- Alectinib for ALK
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
19526 trials
Franklin, IN (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing lepodisiran, a medication given as an injection under the skin. It targets people with high levels of lipoprotein(a) who have cardiovascular disease or are at risk of heart attack or stroke. The medication works by lowering lipoprotein(a) levels to reduce the risk of these cardiovascular events.
Efficacy & Safety Awards
Pivotal Trial
SummaryThis trial will study the effectiveness of a new weight loss treatment called Revita DMR compared to a fake treatment (sham) in helping people maintain weight loss after losing at least 15% of
SummaryThis trial is investigating whether a new diabetes treatment is better than a sham treatment at improving glycemic, hepatic, and cardiovascular outcomes for patients with type 2 diabetes who can't control their blood sugar with insulin therapy.
Greenwood, IN (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to see if using ADT intermittently can improve survival rate & reduce hot flashes in men with mCSPC, with PSA levels <0.2 ng/mL after 6 months of treatment.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Greenwood, IN (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing injections of a drug called tozorakimab in adults with COPD who have frequent flare-ups. These patients are already on other inhaled treatments but still experience significant symptoms. The drug aims to reduce lung inflammation and prevent these flare-ups.
Efficacy & Safety Awards
Pivotal Trial
Greenwood, IN (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial will compare the effectiveness of two different treatments for participants with a specific type of bladder cancer. One group will receive a treatment called TURBT followed by cretostimogene grenadenore
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Greenwood, IN (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test the effectiveness of CG0070, given through the bladder, in patients with NMIBC that has not responded to BCG treatment.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Greenwood, IN (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing Tozorakimab, a medication that aims to reduce lung inflammation, in adults aged 40 and older with COPD. The goal is to see if it can help them breathe better and have fewer symptoms.
Efficacy & Safety Awards
Pivotal Trial
Get notified when new Bladder Cancer trials are postedWe'll send you an email whenever new trials are posted
Greenwood, IN (<10 mi)
Recruiting
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing the safety and effectiveness of a new treatment for high-risk non-muscle-invasive bladder cancer.
Efficacy & Safety Awards
No Placebo-Only Group
Indianapolis, IN (<20 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing ziltivekimab to see if it can help people with heart failure and inflammation by reducing inflammation and improving heart function.
Efficacy & Safety Awards
Pivotal Trial
Indianapolis, IN (<20 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests a combination of two drugs to see if they're better than one drug at preventing breast cancer from coming back in patients with high risk, HER2 positive breast cancer.
Efficacy & Safety Awards
Pivotal Trial
Indianapolis, IN (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing an experimental treatment called DFP-10917 against standard treatments for relapsed or refractory acute myeloid leukemia (AML). Patients in the experimental arm will receive DFP-10917 by continuous intravenous infusion for 14 days, followed by a 14-day resting period, for up to 6 cycles. Patients in the control arm will receive standard treatments, which may include non-intensive reinduction or intensive reinduction, depending on the patient's prior induction treatment.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Indianapolis, IN (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing whether omitting regional radiation therapy for low-risk breast cancer is non-inferior to usual care.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Indianapolis, IN (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Indianapolis, IN (<20 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests if injecting muscle cells can help women who have chronic fecal incontinence due to childbirth injuries. The goal is to see if these injections can repair and strengthen their anal muscles, reducing incontinence episodes. Previous studies have shown that injecting muscle cells into the anal muscles can significantly improve fecal incontinence, particularly in patients with childbirth-related injuries.
Efficacy & Safety Awards
Pivotal Trial
Indianapolis, IN (<20 mi)
Recruiting
Phase 33 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis Trial tests if abatacept can reduce serious heart problems in patients with heart inflammation caused by cancer treatments. Abatacept calms the immune system by preventing certain immune cells from becoming fully active, reducing inflammation and damage. Abatacept has been approved by the US Food and Drug Administration for the treatment of rheumatoid arthritis, with or without methotrexate.
Efficacy & Safety Awards
All Individual Drugs Already Approved
Approved for 5 Other Conditions
Pivotal Trial
Indianapolis, IN (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing whether a combination of surgery and hormone therapy is non-inferior to surgery, hormone therapy, and radiation for treating breast cancer.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Get notified when new Non-Small Cell Lung Cancer trials are postedWe'll send you an email whenever new trials are posted
Indianapolis, IN (<20 mi)
Recruiting
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test new targeted cancer therapies against standard of care therapy in order to find more effective treatments.
Efficacy & Safety Awards
No Placebo-Only Group
Indianapolis, IN (<20 mi)
Recruiting
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will follow up on participants who received gene-modified T cell therapy in a previous study to see if the therapy is safe and effective in the long term.
Efficacy & Safety Awards
No Placebo-Only Group
1
2
3
…50